Last reviewed · How we verify
A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Details
| Lead sponsor | Shanghai Jiao Tong University School of Medicine |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 152 |
| Start date | 2016-07 |
| Completion | 2020-12 |
Conditions
- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Gallbladder Cancer
Interventions
- biological test
- GEMOX
- Cetuximab
- Trastuzumab
- Gefitinib
- Lapatinib
- Everolimus
- Sorafenib
- Crizotinib
Primary outcomes
- Progression Free Survival — up to 1 year
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year. The progression is defined consistent with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria for solid tumors.
Countries
China